- Home
- MGIC vs CGEN Comparison
MGIC vs CGEN Comparison
Compare MGIC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- CGEN
- Stock Information
- Founded
- MGIC 1983
- CGEN 1993
- Country
- MGIC Israel
- CGEN Israel
- Employees
- MGIC N/A
- CGEN N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MGIC Technology
- CGEN Health Care
- Exchange
- MGIC Nasdaq
- CGEN Nasdaq
- Market Cap
- MGIC 788.0M
- CGEN 167.4M
- IPO Year
- MGIC 1991
- CGEN 2000
- Fundamental
- Price
- MGIC $21.34
- CGEN $1.70
- Analyst Decision
- MGIC Buy
- CGEN
- Analyst Count
- MGIC 2
- CGEN 0
- Target Price
- MGIC $16.00
- CGEN N/A
- AVG Volume (30 Days)
- MGIC 76.1K
- CGEN 170.7K
- Earning Date
- MGIC 08-13-2025
- CGEN 08-05-2025
- Dividend Yield
- MGIC 2.77%
- CGEN N/A
- EPS Growth
- MGIC 1.33
- CGEN N/A
- EPS
- MGIC 0.76
- CGEN N/A
- Revenue
- MGIC $569,136,000.00
- CGEN $27,589,000.00
- Revenue This Year
- MGIC $7.53
- CGEN N/A
- Revenue Next Year
- MGIC $8.96
- CGEN $173.80
- P/E Ratio
- MGIC $27.61
- CGEN N/A
- Revenue Growth
- MGIC 6.37
- CGEN N/A
- 52 Week Low
- MGIC $9.64
- CGEN $1.13
- 52 Week High
- MGIC $21.98
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- MGIC 80.60
- CGEN 54.86
- Support Level
- MGIC $20.17
- CGEN $1.62
- Resistance Level
- MGIC $21.98
- CGEN $1.82
- Average True Range (ATR)
- MGIC 0.52
- CGEN 0.08
- MACD
- MGIC 0.29
- CGEN -0.01
- Stochastic Oscillator
- MGIC 88.01
- CGEN 54.17
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.